All In Biotech

Free tool

FAERS Monitor: Elrexfio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761345 or its brand name (Elrexfio, Elranatamab). Reports on generic versions are filed under their own applications.

Reports

1,158

Serious

989

85% of reports

Hospitalization

347

Death reported

279

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cytokine release syndrome207
  • death115
  • malignant neoplasm progression87
  • pyrexia82
  • immune effector cell-associated neurotoxicity syndrome60
  • pneumonia59
  • fatigue58
  • cytomegalovirus infection reactivation57
  • off label use49
  • plasma cell myeloma45
  • rash45
  • infection44
  • diarrhoea40
  • neutropenia40
  • decreased appetite33

Reports by year received

View as table
YearReports
20235
2024190
2025556
2026407

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,001 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cytomegalovirus infection reactivationSignal57237.4184.013,016
cytokine release syndromeSignal207189.4167.338,239
immune effector cell-associated neurotoxicity syndromeSignal60185.9145.110,741
plasma cell myelomaSignal4521.015.7837
malignant neoplasm progressionSignal8715.412.61,165
infectionSignal445.54.1160
neutropeniaSignal405.33.9138
pyrexiaSignal824.33.5208
pneumoniaSignal593.32.694
decreased appetiteSignal332.61.831
deathSignal1152.42.099
rash451.91.418
fatigue581.41.15
diarrhoea401.10.80
off label use491.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.